Evidence map›Paper›PMID 42004149›Full record

ArticleIDCases2026

Probable Loa loa-associated encephalopathy following ivermectin administration in a patient with malaria infection: A case report from the Democratic Republic of the Congo.

Charles Malisaba Posite, Joseph Kasongo Findama, Moïse Kambale Vwiravwahali, Isaac Muhindo Molo, Gabriel Kambale Bunduki

Abstract readCase Reports
In one paragraph

Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles Malisaba PositeDepartment of Pathology, Faculty of Medicine, Université Catholique du Graben, Butembo, Congo.
Joseph Kasongo FindamaCentre Hospitalier Evangélique de Beni, Beni, Congo.
Moïse Kambale VwiravwahaliCentre Hospitalier Evangélique de Beni, Beni, Congo.
Isaac Muhindo MoloCentre Hospitalier Evangélique de Beni, Beni, Congo.
Gabriel Kambale BundukiCentre d'Excellence en Maladies Infectieuses et Soins Critiques du Graben (CEMISoCG), Butembo, Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ivermectin is widely used in mass drug administration programs for the control of onchocerciasis and lymphatic filariasis. In areas where Loa loa is co-endemic, ivermectin administration may precipitate severe neurological adverse events among individuals with high microfilarial densities. We report a case of probable Loa loa-associated encephalopathy following ivermectin administration in a patient with malaria infection. Case presentation: A 37-year-old woman from Ituri Province, eastern Democratic Republic of the Congo, presented with altered mental status after receiving ivermectin for loiasis. Her illness began with colicky abdominal pain, mucoid-bloody diarrhea, and polyarthralgia, followed by unsuccessful self-medication. She was subsequently diagnosed with intestinal parasitosis and malaria at a peripheral health facility and treated accordingly, but her neurological condition worsened. On admission to a referral hospital, blood smear examination revealed Plasmodium trophozoites and Loa loa microfilariae. Within 24 h of ivermectin administration, she developed meningeal signs. Cerebrospinal fluid analysis demonstrated the presence of Loa loa microfilariae, with no evidence of bacterial or fungal infection. Following intensified antimicrobial therapy, initiation of albendazole, and supportive care, her neurological status progressively improved. She was discharged after 19 days of hospitalization, and follow-up evaluation confirmed complete clinical recovery with clearance of microfilariae. Conclusion: This case fuls criteria for probable Loa loa-associated encephalopathy temporally related to ivermectin administration. It highlights the need for heightened clinical vigilance, microfilarial burden assessment when feasible, and strengthened pharmacovigilance before ivermectin use in Loa loa-endemic and co-endemic settings, particularly in patients with concurrent parasitic infections.

Indexed as

Case reportCentral AfricaEncephalopathyIvermectinLoa loaMalariaMass drug administrationNeurotoxicity

Identifiers

PMID42004149
PMCPMC13090541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.